THZ1Covalent CDK7 inhibitor,potent and selective CAS# 1604810-83-4 |
- BS-181 HCl
Catalog No.:BCC2537
CAS No.:1397219-81-6
- PHA-793887
Catalog No.:BCC2521
CAS No.:718630-59-2
- PHA-848125
Catalog No.:BCC3839
CAS No.:802539-81-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1604810-83-4 | SDF | Download SDF |
PubChem ID | 73602827 | Appearance | Powder |
Formula | C31H28ClN7O2 | M.Wt | 566.05 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | CDK7 inhibitor | ||
Solubility | DMSO : 100 mg/mL (176.66 mM; Need ultrasonic) | ||
Chemical Name | N-[3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]phenyl]-4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]benzamide | ||
SMILES | CN(C)CC=CC(=O)NC1=CC=C(C=C1)C(=O)NC2=CC=CC(=C2)NC3=NC=C(C(=N3)C4=CNC5=CC=CC=C54)Cl | ||
Standard InChIKey | OBJNFLYHUXWUPF-IZZDOVSWSA-N | ||
Standard InChI | InChI=1S/C31H28ClN7O2/c1-39(2)16-6-11-28(40)35-21-14-12-20(13-15-21)30(41)36-22-7-5-8-23(17-22)37-31-34-19-26(32)29(38-31)25-18-33-27-10-4-3-9-24(25)27/h3-15,17-19,33H,16H2,1-2H3,(H,35,40)(H,36,41)(H,34,37,38)/b11-6+ | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | THZ1 is an irreversible, potent and selective inhibitor of CDK7(cyclin-dependent kinase 7) with an IC50 value of 3.2 nM. | |||||
Targets | CDK7 | |||||
IC50 | 3.2 nM |
Cell experiment: [1] | |
Cell lines | Jurkat and Loucy T-ALL cell lines |
Preparation method | The solubility of this compound in DMSO is <10 mm. general tips for obtaining a higher concentration: please warm the tube at 37 °c 10 minutes and> |
Reacting condition | 72 hours IC50: 50 nM (for Jurkat cells), 0.55 nM (for Loucy T-ALL cells) |
Applications | As a CDK7 inhibitor, THZ1 potently inhibited proliferation of Jurkat and Loucy T-ALL cell lines with IC50 values of 50 nM and 0.55 nM, respectively. |
Animal experiment: [1] | |
Animal models | Mice bearing KOPTK1 xenografts |
Dosage form | 10 mg/kg, twice daily for 29 days |
Application | THZ1 exhibited efficacy in a bioluminescent xenografted mouse model using the human T-ALL cell-line KOPTK1 when dosed twice daily at 10mg/kg. THZ1waswell tolerated at these doseswith no observable body weight loss or behavioural changes, suggesting that it caused no overt toxicity in the animals. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1] Kwiatkowski N, Zhang T, Rahl P B, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature, 2014, 511(7511): 616-620. |
THZ1 Dilution Calculator
THZ1 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.7666 mL | 8.8331 mL | 17.6663 mL | 35.3326 mL | 44.1657 mL |
5 mM | 0.3533 mL | 1.7666 mL | 3.5333 mL | 7.0665 mL | 8.8331 mL |
10 mM | 0.1767 mL | 0.8833 mL | 1.7666 mL | 3.5333 mL | 4.4166 mL |
50 mM | 0.0353 mL | 0.1767 mL | 0.3533 mL | 0.7067 mL | 0.8833 mL |
100 mM | 0.0177 mL | 0.0883 mL | 0.1767 mL | 0.3533 mL | 0.4417 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
THZ1 is a covalent inhibitor of CDK7 with IC50 value of 3.2nM [1].
THZ1 covalently modifies CDK7 by targeting C312 residue outside of the kinase domain, providing an unanticipated means of achieving covalent selectivity. THZ1 potently inhibits proliferation of Jurkat and Loucy T-ALL cell lines with IC50 values of 50nM and 0.55nM, respectively. In the kinase binding assay, THZ1 shows a good binding affinity with IC50 value of 3.2nM [1].
As an inhibitor of CDK7, THZ1 inhibits the phosphorylation of the C-terminal domain of RNAP polymerase II, effecting the regulation of transcription. THZ1 also inhibits the activation of the CDK proteins. It is reported to disrupt the CDK7 signalling pathways both in Jurkat cells and Loucy cells. THZ1 shows a broad-based activity with IC50 values less than 200nM in a variety of cancer cell lines. Among these cell lines, T-ALL is exceptional sensitivity to THZ1 due to the transcription effect of RUNX1 caused by THZ1 [1].
References:
[1] Nicholas Kwiatkowski, Tinghu Zhang, Peter B. Rahl et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature, 2014.
- 30-Oxopseudotaraxasterol
Catalog No.:BCN7135
CAS No.:160481-71-0
- 3',5,5',7-Tetrahydroxyflavanone
Catalog No.:BCN1710
CAS No.:160436-10-2
- X-NeuNAc
Catalog No.:BCC2063
CAS No.:160369-85-7
- Bisdehydroneotuberostemonine
Catalog No.:BCN7072
CAS No.:160333-27-7
- L-368,899 hydrochloride
Catalog No.:BCC7438
CAS No.:160312-62-9
- 8-Hydroxybergapten
Catalog No.:BCN2732
CAS No.:1603-47-0
- SB 205384
Catalog No.:BCC7095
CAS No.:160296-13-9
- 14-Deoxy-11-hydroxyandrographolide
Catalog No.:BCN4702
CAS No.:160242-09-1
- SR 11302
Catalog No.:BCC3607
CAS No.:160162-42-5
- BIM 23127
Catalog No.:BCC5822
CAS No.:160161-61-5
- 7-Chloro-1,2,3,4-tetrahydrobenzo[b]azepin-5-one
Catalog No.:BCC8779
CAS No.:160129-45-3
- L-BMAA hydrochloride
Catalog No.:BCC7400
CAS No.:16012-55-8
- THZ2
Catalog No.:BCC3986
CAS No.:1604810-84-5
- Antirhine
Catalog No.:BCN4003
CAS No.:16049-28-8
- Bisandrographolide A
Catalog No.:BCN4701
CAS No.:160498-00-0
- 12S-hydroxyandrographolide
Catalog No.:BCN4700
CAS No.:869593-50-0
- BW 723C86 hydrochloride
Catalog No.:BCC6915
CAS No.:160521-72-2
- 5,7,3',4'-Tetrahydroxy-3-methoxy-8-geranylflavone
Catalog No.:BCN6847
CAS No.:1605304-56-0
- Zarzissine
Catalog No.:BCN6456
CAS No.:160568-14-9
- DMP 543
Catalog No.:BCC7331
CAS No.:160588-45-4
- Villosin
Catalog No.:BCN1711
CAS No.:160598-92-5
- 1,4,6-Trihydroxy-5-methoxy-7-prenylxanthone
Catalog No.:BCN1548
CAS No.:160623-47-2
- 2,3-Dihydro-3alpha-methoxynimbolide
Catalog No.:BCN7093
CAS No.:1607828-35-2
- Ardisicrenoside B
Catalog No.:BCN8078
CAS No.:160791-12-8
THZ1 Reveals Roles for Cdk7 in Co-transcriptional Capping and Pausing.[Pubmed:26257281]
Mol Cell. 2015 Aug 20;59(4):576-87.
The Cdk7 subunit of TFIIH phosphorylates RNA polymerase II (Pol II) during initiation, and, while recent studies show that inhibition of human Cdk7 negatively influences transcription, the mechanisms involved are unclear. Using in vitro transcription with nuclear extract, we demonstrate that THZ1, a covalent Cdk7 inhibitor, causes defects in Pol II phosphorylation, co-transcriptional capping, promoter proximal pausing, and productive elongation. THZ1 does not affect initiation but blocks essentially all Pol II large subunit C-terminal domain (CTD) phosphorylation. We found that guanylylation of nascent RNAs is length dependent and modulated by a THZ1-sensitive factor present in nuclear extract. THZ1 impacts pausing through a capping-independent block of DSIF and NELF loading. The P-TEFb-dependent transition into productive elongation was also inhibited by THZ1, likely due to loss of DSIF. Capping and pausing were also reduced in THZ1-treated cells. Our results provide mechanistic insights into THZ1 action and how Cdk7 broadly influences transcription and capping.
THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors.[Pubmed:28134252]
Nat Commun. 2017 Jan 30;8:14290.
Peripheral T-cell lymphomas (PTCL) are aggressive diseases with poor response to chemotherapy and dismal survival. Identification of effective strategies to target PTCL biology represents an urgent need. Here we report that PTCL are sensitive to transcription-targeting drugs, and, in particular, to THZ1, a covalent inhibitor of cyclin-dependent kinase 7 (CDK7). The STAT-signalling pathway is highly vulnerable to THZ1 even in PTCL cells that carry the activating STAT3 mutation Y640F. In mutant cells, CDK7 inhibition decreases STAT3 chromatin binding and expression of highly transcribed target genes like MYC, PIM1, MCL1, CD30, IL2RA, CDC25A and IL4R. In surviving cells, THZ1 decreases the expression of STAT-regulated anti-apoptotic BH3 family members MCL1 and BCL-XL sensitizing PTCL cells to BH3 mimetic drugs. Accordingly, the combination of THZ1 and the BH3 mimetic obatoclax improves lymphoma growth control in a primary PTCL ex vivo culture and in two STAT3-mutant PTCL xenografts, delineating a potential targeted agent-based therapeutic option for these patients.